FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2330331796> ?p ?o ?g. }

• W2330331796 endingPage "S322" @default.
• W2330331796 startingPage "S322" @default.
• W2330331796 abstract "Targeting T cells alone has yielded limited success in the prevention of graft versus host disease (GvHD) after allogeneic blood and marrow transplantation (BMT). Dendritic cells (DCs) play a central role in alloreactivity and therefore represent a suitable target. Due to their immune modulatory effects and their inhibition of maturation and function of DC, proteasome inhibitors have prompted investigators to examine their potential role in the prevention of GvHD. Ixazomib is a specific and reversible proteasome inhibitor with rapid dissociation from 20S proteasome. It is orally bioavailable. We aimed to explore its effect on healthy volunteer DCs. DCs were isolated using EasySep Pan-DC Pre-Enrichment Cocktail with a purity over 90% (STEMCELL Technologies). DCs were treated with ixazomib at different concentrations for 4 hrs and then stimulated with Lipopolysaccharide (LPS) for 16 hrs. After the treatment, DCs were surface stained with antibodies against maturation markers and analyzed by flow cytometry. DC survival was evaluated with 7AAD staining and FACS analysis. To assess the effect of ixazomib on the production of pro-inflammatory cytokines, DCs were incubated with ixazomib at increasing concentration before or after addition of LPS. Pro-inflammatory cytokines in the supernatant of tissue culture were measured using EMD Millipore cytokine arrays. Experiments were done in triplicate at least. Unpaired T test was used for statistical analysis. P < 0.05 was considered significant. Ixazomib inhibited expression of 6 DC maturation markers including CD40, CD54, CD80, CD83, CD86 and CD197 (CCR-7). The inhibition started at a concentration of 10 nM and was dose related. Ixazomib also decreased the percentage of DCs simultaneously expressing multiple markers. DCs viability remained unchanged in comparison to control at a concentration of 10 nM and dropped to 68% and 43% on average with concentrations of 20 nM and 40 nM. There was no significant change in the cytokine production when ixazomib was added 4 hours after LPS. On the other hand, ixazomib significantly decreased production of IL-6 and IL-23 by DCs at the concentration of 20-30 nM. However, there was no significant change of TNF-β and INF-γ upon ixazomib treatments. In summary, ixazomib inhibits DC maturation with relative preservation of cell viability. On the other hand, ixazomib inhibits pro-inflammatory cytokine production in DCs only when it is added before LPS stimulation. This may have clinical implications and suggests that adequate inhibition of DCs before graft infusion might be essential to the prevention GvHD." @default.
• W2330331796 created "2016-06-24" @default.
• W2330331796 creator A5005993632 @default.
• W2330331796 creator A5019509968 @default.
• W2330331796 creator A5045479705 @default.
• W2330331796 creator A5081036799 @default.
• W2330331796 creator A5091902341 @default.
• W2330331796 date "2015-02-01" @default.
• W2330331796 modified "2023-09-23" @default.
• W2330331796 title "Ixazomib Inhibits Dendritic Cell Maturation and Function" @default.
• W2330331796 doi "https://doi.org/10.1016/j.bbmt.2014.11.512" @default.
• W2330331796 hasPublicationYear "2015" @default.
• W2330331796 type Work @default.
• W2330331796 sameAs 2330331796 @default.
• W2330331796 citedByCount "0" @default.
• W2330331796 crossrefType "journal-article" @default.
• W2330331796 hasAuthorship W2330331796A5005993632 @default.
• W2330331796 hasAuthorship W2330331796A5019509968 @default.
• W2330331796 hasAuthorship W2330331796A5045479705 @default.
• W2330331796 hasAuthorship W2330331796A5081036799 @default.
• W2330331796 hasAuthorship W2330331796A5091902341 @default.
• W2330331796 hasBestOaLocation W23303317961 @default.
• W2330331796 hasConcept C126322002 @default.
• W2330331796 hasConcept C154317977 @default.
• W2330331796 hasConcept C202751555 @default.
• W2330331796 hasConcept C203014093 @default.
• W2330331796 hasConcept C2776090121 @default.
• W2330331796 hasConcept C2776364478 @default.
• W2330331796 hasConcept C2778170410 @default.
• W2330331796 hasConcept C2778297628 @default.
• W2330331796 hasConcept C2778367456 @default.
• W2330331796 hasConcept C2780108899 @default.
• W2330331796 hasConcept C2781098529 @default.
• W2330331796 hasConcept C2781101188 @default.
• W2330331796 hasConcept C2911091166 @default.
• W2330331796 hasConcept C39347974 @default.
• W2330331796 hasConcept C553184892 @default.
• W2330331796 hasConcept C55493867 @default.
• W2330331796 hasConcept C71924100 @default.
• W2330331796 hasConcept C86803240 @default.
• W2330331796 hasConcept C8891405 @default.
• W2330331796 hasConcept C98274493 @default.
• W2330331796 hasConceptScore W2330331796C126322002 @default.
• W2330331796 hasConceptScore W2330331796C154317977 @default.
• W2330331796 hasConceptScore W2330331796C202751555 @default.
• W2330331796 hasConceptScore W2330331796C203014093 @default.
• W2330331796 hasConceptScore W2330331796C2776090121 @default.
• W2330331796 hasConceptScore W2330331796C2776364478 @default.
• W2330331796 hasConceptScore W2330331796C2778170410 @default.
• W2330331796 hasConceptScore W2330331796C2778297628 @default.
• W2330331796 hasConceptScore W2330331796C2778367456 @default.
• W2330331796 hasConceptScore W2330331796C2780108899 @default.
• W2330331796 hasConceptScore W2330331796C2781098529 @default.
• W2330331796 hasConceptScore W2330331796C2781101188 @default.
• W2330331796 hasConceptScore W2330331796C2911091166 @default.
• W2330331796 hasConceptScore W2330331796C39347974 @default.
• W2330331796 hasConceptScore W2330331796C553184892 @default.
• W2330331796 hasConceptScore W2330331796C55493867 @default.
• W2330331796 hasConceptScore W2330331796C71924100 @default.
• W2330331796 hasConceptScore W2330331796C86803240 @default.
• W2330331796 hasConceptScore W2330331796C8891405 @default.
• W2330331796 hasConceptScore W2330331796C98274493 @default.
• W2330331796 hasIssue "2" @default.
• W2330331796 hasLocation W23303317961 @default.
• W2330331796 hasOpenAccess W2330331796 @default.
• W2330331796 hasPrimaryLocation W23303317961 @default.
• W2330331796 hasRelatedWork W2045408599 @default.
• W2330331796 hasRelatedWork W2138751577 @default.
• W2330331796 hasRelatedWork W2253345118 @default.
• W2330331796 hasRelatedWork W2356873867 @default.
• W2330331796 hasRelatedWork W2369869607 @default.
• W2330331796 hasRelatedWork W2378148158 @default.
• W2330331796 hasRelatedWork W2383537368 @default.
• W2330331796 hasRelatedWork W2384816639 @default.
• W2330331796 hasRelatedWork W2394744011 @default.
• W2330331796 hasRelatedWork W2507705066 @default.
• W2330331796 hasVolume "21" @default.
• W2330331796 isParatext "false" @default.
• W2330331796 isRetracted "false" @default.
• W2330331796 magId "2330331796" @default.
• W2330331796 workType "article" @default.